The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates nuclear factor-kappa B (NF-jB) and induces pro-inflammatory gene expression; however, the mechanism of this activation is unknown. To address this, we expressed RP3 in murine embryonic fibroblasts (MEFs) lacking key classical and noncanonical NF-jB signaling components. In wild-type MEFs, RP3 upregulated CCL2, CXCL1, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor expression and activated classical but not noncanonical NF-jB. RP3-activated NF-jB in IjB kinase (IKK)b À/À MEFs but not IKKa-or NF-jB essential modulator (NEMO)-deficient cells and activation was inhibited by a peptide that blocks NEMO binding to the IKKs. RP3 increased the levels of NF-jB-inducing kinase (NIK) and did not activate NF-jB in NIK-deficient MEFs. Notably, NIK stabilization was not accompanied by TRAF3 degradation demonstrating that RP3 disrupts normal basal NIK regulation. Dominant-negative NIK blocked RP3-induced NF-jB activation and an RP3 signaling mutant (RP3 Y588F ) did not stabilize NIK. Finally, examination of PTC specimens revealed strong positive staining for NIK. We therefore conclude that RP3 activates classical NF-jB via NIK, NEMO and IKKa. Importantly, our findings reveal a novel mechanism for oncogene-induced NF-jB activation via stabilization of NIK.
The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates nuclear factor-kappa B (NF-jB) and induces pro-inflammatory gene expression; however, the mechanism of this activation is unknown. To address this, we expressed RP3 in murine embryonic fibroblasts (MEFs) lacking key classical and noncanonical NF-jB signaling components. In wild-type MEFs, RP3 upregulated CCL2, CXCL1, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor expression and activated classical but not noncanonical NF-jB. RP3-activated NF-jB in IjB kinase (IKK)b À/À MEFs but not IKKa-or NF-jB essential modulator (NEMO)-deficient cells and activation was inhibited by a peptide that blocks NEMO binding to the IKKs. RP3 increased the levels of NF-jB-inducing kinase (NIK) and did not activate NF-jB in NIK-deficient MEFs. Notably, NIK stabilization was not accompanied by TRAF3 degradation demonstrating that RP3 disrupts normal basal NIK regulation. Dominant-negative NIK blocked RP3-induced NF-jB activation and an RP3 signaling mutant (RP3 Introduction Aberrant nuclear factor-kappa B (NF-kB) activation occurs in many cancers (Karin, 2006) where it is implicated in tumorigenesis by promoting the expression of anti-apoptotic genes and pro-inflammatory cytokines that cumulatively influence cell survival and tumor progression (Basseres and Baldwin, 2006; Karin, 2006) . The NF-kB transcription factor family contains five members named NF-kB1 (p105/p50), NF-kB2 (p100/ p52), RelA (p65), RelB and c-Rel that form homo-or heterodimers, which are normally held inactive in the cytosol by a group of proteins named the inhibitors of kB or IkBs (Hayden and Ghosh, 2008) . On stimulation, the IkBs become rapidly phosphorylated, ubiquitinated and degraded by the 26S proteasome. This releases NF-kB that translocates to the nucleus to promote target gene transcription (Hayden and Ghosh, 2008) . In many tumor cells, this normal regulation is dysfunctional, leading to sustained nuclear localization of NF-kB (Basseres and Baldwin, 2006; Karin, 2006) . NF-kB activation is regulated by the IkB kinase (IKK) complex that contains two catalytic subunits, IKKa (IKK1) and IKKb (IKK2), and a regulatory subunit named NF-kB essential modulator (NEMO) (Hayden and Ghosh, 2008) . Deletion of these revealed two separate pathways of NF-kB activation. The classical NF-kB pathway, requires NEMO-and IKKbmediated phosphorylation of IkBs leading to nuclear translocation of NF-kB typified by p65:p50 (Hayden and Ghosh, 2008) . This pathway is activated by most immune and inflammatory stimuli and is critical for inflammation, immunity, cell survival and proliferation. Aberrant classical NF-kB activation has been extensively described in cancer (Basseres and Baldwin, 2006; Karin, 2006) .
The second mechanism is the noncanonical pathway that requires IKKa activation by NF-kB-inducing kinase (NIK) independently of NEMO and IKKb (Senftleben et al., 2001; Xiao et al., 2001) . In resting cells, NIK is normally degraded via ubiquitination involving TRAF2 and TRAF3 (He et al., 2007; Vallabhapurapu et al., 2008; Zarnegar et al., 2008) . Following stimulation, TRAF3 is degraded and NIK levels accumulate and activate IKKa. IKKa then phosphorylates p100 associated with RelB leading to p100 processing to p52 and release of a p52:RelB heterodimer (Senftleben et al., 2001; Xiao et al., 2001; He et al., 2007; Vallabhapurapu et al., 2008; Zarnegar et al., 2008) . This NF-kB species regulates lymphoid organogenesis and B-cell maturation (Dejardin et al., 2002) and aberrant noncanonical signaling occurs in various cancers (Annunziata et al., 2007; Keats et al., 2007; Nishina et al., 2009; Wharry et al., 2009) . Recent studies revealed that mutations in NIK or its regulators stabilize NIK and activate both NF-kB pathways in cancer cells (Annunziata et al., 2007; Keats et al., 2007) .
The RET proto-oncogene encodes a receptor tyrosine kinase absent in normal thyroid tissue (Bunone et al., 2000) . However, in thyroid malignancies, RET translocates to form fusions of its kinase domain attached to one of several constitutively active gene partners (Bunone et al., 2000) . These translocations constitute a family of fusion proteins termed the RET/papillary thyroid carcinomas (PTCs) of which RET/PTC1 and RET/PTC3 (RP3) are the most prevalent (Ciampi and Nikiforov, 2007) . The RET/PTCs occur in PTC and intriguingly RET/PTC expression is observed in PTC associated with autoimmune thyroiditis as well as autoimmune thyroiditis with no detectable cancer (Wirtschafter et al., 1997; Sheils et al., 2000; Rhoden et al., 2006) . Hence, the RET/PTC oncogenes may provide a molecular link between autoimmune inflammatory thyroiditis and thyroid cancer (Eisenlohr and Rothstein, 2006; Muzza et al., 2009) .
The un-rearranged RET receptor activates classical NF-kB (Hayashi et al., 2000; Ludwig et al., 2001) and constitutive NF-kB activity occurs in thyroid cancer cell lines (Visconti et al., 1997; Pacifico et al., 2004) and tissue samples of papillary, follicular and anaplastic thyroid cancer (Pacifico and Leonardi, 2010) . More importantly, ectopic RP3 expression activates NF-kB and induces pro-inflammatory cytokines and chemokines including granulocyte-macrophage colony-stimulating factor (GM-CSF), and CCL2 that are targets of the classical NF-kB pathway (Russell et al., 2003; Pufnock and Rothstein, 2009 ). In addition, RET/PTC1 induces a pro-inflammatory gene program characterized by classical NF-kB-dependent chemokines, cytokines and growth factors (Borrello et al., 2005) . Although these studies establish that RET and the RET/PTCs activate classical NF-kB, several lines of evidence indicate that these proteins might also regulate noncanonical NF-kB signaling. Thus, RET null mice fail to develop Peyer's Patches indicating defective lymphoid organogenesis although this phenotype has not been linked to defects in noncanonical NF-kB signaling (Veiga-Fernandes et al., 2007) . More directly, RET/PTC1 expression in thyrocytes induces the noncanonical NF-kB-dependent gene CXCL12 (Borrello et al., 2005) . Despite this accumulated evidence, the precise mechanism of NF-kB activation by the RET/PTCs remains unknown.
To address this question, we expressed RP3 in mouse embryonic fibroblasts (MEFs) lacking key components of the classical and noncanonical NF-kB pathways and determined the effects of RP3 on NF-kB activation and gene expression. We demonstrate that RP3 activates classical NF-kB via a novel pathway involving NIK, NEMO and IKKa. Importantly, our findings reveal an unanticipated mechanism for oncogene-induced NF-kB activation via stabilization of NIK.
Results

RP3 activates NF-kB and induces pro-inflammatory gene expression in MEFs
To study the mechanism of RP3-induced NF-kB activation, we retrovirally transduced MEFs with either the MIGR1 control vector, or MIGR1-containing RP3 (MIGR1-RP3) (Russell et al., 2003; Pufnock and Rothstein, 2009 ). Immunoblotting of cell lysates using anti-RET antibody revealed RP3 expression restricted to the RP3-transduced cells (Figure 1a ). To determine whether ectopic RP3 expression could activate NF-kB, control and RP3-transduced MEFs were transiently transfected with an NF-kB luciferase reporter plasmid and transcription was assessed by luciferase assay. Consistent with previous studies using thyrocytes (Russell et al., 2003; Pufnock and Rothstein, 2009 ), NF-kB activity was enhanced in MEFs expressing RP3 compared with control cells (Figure 1b) . Furthermore, . After 24 h, NF-kB activity was determined by dual-luciferase assay in each stable line as the ratio of the relative luciferase units (FFL:RL). Results are expressed as fold increase normalized to the control cells. (c) Nuclear extracts from control (Con) and RP3-expressing MEFs were prepared for electrophoretic mobility shift assay (EMSA) (top two panels). Assays were performed using either a consensus NF-kB-binding site probe or an Oct1 probe as a loading control as shown (right). Whole cell lysates from the same cells were immunoblotted (IB) using the antibodies indicated (right). (d) Expression of the NF-kB-dependent genes CXCL1, CCL2, GM-CSF and TNF in control and RP3-expressing MEFs was measured by quantitative reverse transcriptase (qRT)-PCR. RQ levels for each gene were normalized to levels in untreated control MEFs.
RET/PTC3 activates NF-jB via NIK RJ Neely et al DNA binding of two distinct NF-kB complexes was markedly enhanced in RP3-expressing cells (Figure 1c ). RET/PTC fusions, including RP3, induce pro-inflammatory gene expression in thyroid cells (Russell et al., 2003; Borrello et al., 2005) . We therefore asked if RP3 affected known NF-kB target genes in MEFs. As shown in Figure 1d , expression of CXCL1, CCL2, tumor necrosis factor (TNF) and GM-CSF, were significantly enhanced in MEFs expressing RP3 compared with control cells. As these are classical NF-kB targets, we questioned whether RP3 could also induce expression of the noncanonical NF-kB-dependent gene CXCL12 (Dejardin et al., 2002; Madge et al., 2008) ; however, this was not induced by RP3 (Supplementary Figure S1) . Thus, ectopic RP3 expression activates NF-kB and induces expression of classical NF-kB-dependent proinflammatory genes.
RP3 activates classical NF-kB NF-kB activation requires signal-induced phosphorylation of the IKKs at specific residues within their activation domains (Hayden and Ghosh, 2008) . To determine whether RP3 induced the phosphorylation of the IKKs, we immunoblotted Control and RP3-MEF lysates using an antibody specific for epitopes on phosphorylated IKKs (anti-p-IKKa/b). As shown in Figure 2a , two immunoreactive bands were detected in RP3-expressing cell lysates (top panel) suggesting that RP3 induces the phosphorylation of both IKKa and IKKb.
A critical signaling event during classical NF-kB activation is site-specific IkBa phosphorylation at Serines 32 and 36 (Hayden and Ghosh, 2008) . As shown in Figure 2b , using an antibody that recognizes IkB phosphorylated at Ser32 (anti-p-IkBa), we detected phospho-IkBa in the RP3-expressing MEFs but not in control cells. A further posttranslational modification critical for classical NF-kB transcriptional activity is phosphorylation of p65 at Ser536 (Hayden and Ghosh, 2008) and we found this modification using antiphospho-S536 (anti-p-p65) only in RP3-expressing cells (Figure 2b ). Together, these findings demonstrate that RP3 induces two major phosphorylation events in the classical NF-kB pathway. Notably, the level of IkBa was markedly enhanced in RP3 cells ( Figure 2b ). As the gene encoding IkBa is a target of classical NF-kB (Hayden and Ghosh, 2008) , its increased expression supports the conclusion that RP3 activates classical NF-kB in MEFs. Whole cell lysates from control (Con) and RP3-expressing MEFs were immunoblotted using the antibodies specified on the right of each panel. (c) The same lysates were immunoblotted using either antip100/p52 (top two panels) or anti-phospho-p100 (p-p100) as shown. (d) WT MEFs were either untreated (À) or incubated with antiLTbR (aLTbR) for 8 h ( þ ) then lysates were immunoblotted using anti-p100/p52 (top two panels) or anti-tubulin. (e) cytoplasmic (Cyto.) and nuclear (Nuc.) extracts from control and RP3-expressing MEFs were immunoblotted using the antibodies indicated (right). Samples were immunoblotted using anti-tubulin and anti-histone H3 (H3) antibodies to control for cytoplasmic and nuclear integrity and protein loading. (f) Nuclear extracts from control (Con), RP3-expressing MEFs and MEFs stimulated with TNF (10 ng/ml; 15 min) were prepared for electrophoretic mobility shift assay (EMSA) either a consensus NF-kB-binding site probe or an Oct1 probe as a loading control. The positions of two DNA-binding complexes are indicated (C1 and C2). (g) The nuclear extracts from RP3-expressing and TNF-stimulated MEFs shown in (f) were used for supershift analysis. Samples were incubated with either a nonspecific isotype-matched control antibody (ns) or anti-NF-kB antibodies as shown (top). The positions of the NF-kB complexes (C1 and C2) and the supershifted bands (SS) are indicated.
RET/PTC3 activates NF-jB via NIK RJ Neely et al Noncanonical NF-kB signaling involves phosphorylation and processing of p100 to p52 (Senftleben et al., 2001; Xiao et al., 2001) . Immunoblotting using antip100/p52 or anti-phospho-p100 showed increased phospho-p100 and p52 levels in RP3-expressing cells compared with control MEFs (Figure 2c ). However, RP3 upregulated p100 expression suggesting that increased p52 is a consequence of enhanced basal p100 levels rather than signal-induced p100 processing. In this regard, treatment of MEFs with an anti-LTb receptor antibody that activates the noncanonical pathway led to the expected decrease in p100 and concomitant increase in p52 (Figure 2d ). Like IkBa, p100 is regulated by classical NF-kB (Hayden and Ghosh, 2008) and this accounts for its increased expression in cells in which the classical but not the noncanonical pathway is activated. Thus, we conclude that RP3 does not activate the noncanonical pathway (that is, promote p100 processing to p52), but instead, its effects resemble those of TNF that increases p100 levels and concomitantly increases p52 via basal processing (Derudder et al., 2003) .
We next explored the nature of the NF-kB proteins in the nucleus of RP3-expressing cells and found that nuclear p65 was increased compared with control cells (Figure 2e ). In contrast, the level of nuclear p50 was lower than control MEFs (Figure 2e) . Furthermore, the amounts of nuclear p52 and RelB in RP3-transduced cells were no different from the levels in control MEFs although both were increased in the cytoplasm of RP3-transduced cells. Comparison of the nuclear NF-kB complexes induced by either RP3 or TNF by electrophoretic mobility shift assay demonstrated significant similarities such that both stimuli upregulated the DNAbinding of two distinct complexes (Figure 2f ). Supershift analysis revealed that the lower complex (C2) induced by both stimuli was completely upshifted by anti-p50 but not by anti-p65, p52, or RelB (Figure 2g ) demonstrating that C2 is a p50 homodimer. In contrast, the upper band (C1) was upshifted by only p65 indicating a p65 homodimer. A small residual band was observed in the p65 supershift that we conclude to be nonspecific, as it was not shifted by any of the antibodies including anti-c-Rel (not shown). These findings demonstrate that RP3 induces a similar NF-kB complex profile as TNF and thereby strongly support the notion that RP3 activates classical but not noncanonical NF-kB.
NF-kB activation is NEMO and IKKa-dependent Classical NF-kB activation typically requires IKKb (Hayden and Ghosh, 2008) ; however, we demonstrated recently that IKKa is sufficient for interleukin-1-induced classical signaling (Solt et al., 2007) . To establish which IKK subunits are required for RP3-induced NF-kB activation, we stably transduced IKKa À/À and IKKb À/À MEFs with RP3. Western blotting confirmed that the MEFs lacked the appropriate kinases and that RP3 was expressed in the transduced cells (Figures 3a and b) . NF-kB activation was no greater in RP3-expressing IKKa À/À MEFs than basal activity in control cells (Figure 3a , Supplementary Figure S2) ; however, similar to wild-type (WT) cells (Figure 1b and Supplementary Figure S2) , NF-kB DNA-binding was markedly enhanced in RP3-expressing IKKb À/À MEFs (Figure 3b and Supplementary Figure S2 ). Consistent with these findings, NF-kB transcriptional activity was increased in WT and IKKb À/À MEFs expressing RP3, whereas RP3 had no effect on transcription in IKKa-deficient cells (Figure 3c ).
To determine whether NEMO is required for RP3-induced NF-kB activation, we stably transduced NEMO À/À MEFs with RP3 or MIGR1 vector alone (Figure 4a ). Similar to IKKa À/À cells, RP3 did not induce NF-kB DNA-binding in NEMO-deficient MEFs above that observed in control cells (Figure 4a) . Furthermore, RP3 did not activate NF-kB transcriptional activity in the absence of NEMO demonstrating RET/PTC3 activates NF-jB via NIK RJ Neely et al that NEMO is required for the RP3-induced NF-kB activation (Figure 4b ). We next asked whether direct association of NEMO with the IKKs is required for RP3-induced NF-kB activation. To address this, we used a cell permeable NEMO-binding domain (NBD) peptide that prevents NEMO binding to IKKa and IKKb (May et al., 2000) . As shown in Figure 4c , treatment of RP3-expressing MEFs with the WT peptide (NBD WT ) but not an inactive mutant control (NBD MUT ) inhibited NF-kB DNA-binding activity. Consistent with this, NBD WT reduced CCL2 expression in RP3-expressing MEFs (Figure 4d ). These accumulated findings lead us to conclude that RP3 activates classical NF-kB via a NEMO-and IKKa-dependent mechanism.
Ectopic RP3 expression stabilizes NIK Recently, aberrant NIK expression was shown to activate classical NF-kB in certain tumor cells (Annunziata et al., 2007; Keats et al., 2007) . We therefore questioned whether RP3 affects the levels of NIK or the proteins that regulate NIK expression, TRAF2 and TRAF3 (He et al., 2007; Vallabhapurapu et al., 2008) . We found that RP3-expressing MEFs contained elevated levels of NIK protein compared with control cells in which NIK was either absent or minimally expressed (Figure 5a) . Surprisingly, unlike signal-induced NIK stabilization that requires TRAF3 degradation (He et al., 2007; Vallabhapurapu et al., 2008) , TRAF3 levels were slightly increased in RP3-transduced MEFs compared with control cells. Quantitative reverse transcriptase-PCR demonstrated similar levels of NIK transcription between RP3 and control cells (Supplementary Figure S3) ; thus, RP3 stabilizes NIK protein levels without causing TRAF3 degradation.
To establish whether NIK is necessary for RP3-induced NF-kB activation, we transduced NIK À/À MEFs with RP3 or the empty MIGR1 vector. We assessed NF-kB activation by luciferase reporter assay and as shown in Figure 5b , RP3 did not activate NF-kB in NIK À/À cells. Furthermore, transient overexpression of dominant-negative NIK, inhibited NF-kB in RP3-expressing WT MEFs (Figure 5c ). Consistent with the ability of RP3 to stabilize endogenous NIK, the amount of dominant-negative NIK was enhanced in RP3 cells (Figure 5c ). Overall, the findings in Figure 5 demonstrate that RP3 expression stabilizes NIK levels independently of TRAF3 degradation and that NIK is required for RP3-induced NF-kB activation.
Earlier studies established that activated RET autophosphorylates tyrosine 1062 forming a Shc docking site that mediates activation of downstream signals (Hayashi et al., 2000) . Moreover, an RP3 mutant containing a tyrosine to phenylalanine substitution at the equivalent residue (RP3 Y588F ) did not activate NF-kB or induce inflammatory gene expression in thyrocytes or fibrosarcoma cells (Russell et al., 2003; Pufnock and Rothstein, 2009 . Compared with RP3, RP3 Y588F did not stabilize NIK levels above those in control MEFs (Figure 6a ) and consistent with previous reports (Russell et al., 2003; Pufnock and Rothstein, 2009) 
, RP3
Y588F did not activate NF-kB (Figure 6b ). Furthermore, although RP3 Y588F partially induced CCL2 expression, this was significantly less than the levels induced by RP3 (Figure 6c ). Thus, we conclude that RP3-induced NIK stabilization and NF-kB activation requires autophosphorylation of Y588.
NIK is expressed in thyroid carcinoma tissue
To establish whether NIK is expressed in human PTC specimens, we immunohistochemically stained tissue blocks from patients with well differentiated RETpositive PTC (Figure 7 ). Staining for RET was similar to that detailed earlier (Nibu et al., 2005) and appeared À/À MEFs transduced with either MIGR vector alone (Con) or MIGR-expressing RP3 were prepared for electrophoretic mobility shift assay (EMSA) (top two panels). Assays were performed using either an NF-kB-binding site probe or an Oct1 probe as shown (right). Whole cell lysates from the same cells were immunoblotted (IB) using the antibodies indicated (right). (b) Control (Con) and RP3-expressing WT and NEMO À/À MEFs were transiently transfected with pBIIx-firefly luciferase and b-actin renilla luciferase. NF-kB activity was determined and the results are expressed as described in Figure 3c . (c) WT MEFs stably transduced with RP3 were incubated for 8 h with either vehicle alone (1% dimethylsulphoxide (DMSO); no pep), 100 mM of the mutant NBD peptide NBD MUT or 50 and 100 mM of the WT peptide (NBD WT ). NF-kB activation in nuclear extracts was determined by EMSA using a consensus NF-kB-binding site probe or an Oct1 probe as a loading control. (d) Control and RP3-expressing MEFs were incubated with either vehicle alone (1% DMSO; -) or NBD WT peptide (100 mM) and expression of CCL2 was measured by quantitative reverse transcriptase (qRT)-PCR. RQ levels were normalized to levels in untreated control MEFs.
RET/PTC3 activates NF-jB via NIK RJ Neely et al homogeneous throughout the tumor tissue whereas vascular endothelial cells were negative ( Figure 7b ). As previously described (Pacifico and Leonardi, 2010; Pacifico et al., 2004; Visconti et al., 1997) , a high number of tumor cells stained positively for nuclear p65 indicating activation of classical NF-kB (Figure 7c ). Endothelial cells did not display any nuclear staining demonstrating that NF-kB activation is limited to the tumor cells. Staining with anti-NIK revealed strong positive immunoreactivity in tumor tissues whereas endothelial cells were uniformly negative (Figure 7d) . Consistent with previous studies demonstrating that NIK shuttles between the cytoplasm and nucleus (Birbach et al., 2004) , NIK was expressed in both compartments in neoplastic cells. These immunohistochemical data therefore demonstrate active NF-kB and NIK expression in PTC cells but not in adjacent nonmalignant endothelial cells within the tumor tissue.
Discussion
Understanding how oncogenes dysregulate normal signaling mechanisms to convert cells from quiescent tissue components into invasive lesions is critical for developing effective anticancer strategies. In this study, we show that the oncogenic fusion protein RP3 aberrantly activates NF-kB signaling by stabilizing the normally absent or minimally expressed NIK protein.
Most importantly, our findings provide the first evidence of an oncogene modulating NIK protein levels to activate classical NF-kB.
Although NF-kB activation has been reported in thyroid malignancies, (Pacifico and Leonardi, 2010 ) the mechanisms controlling aberrant NF-kB in thyroid cancer are poorly understood. Ectopic RP3 expression in MEFs induced classical NF-kB signaling and nuclear accumulation of p65, but did not activate noncanonical À/À MEFs were transiently transfected with pBIIxfirefly luciferase and b-actin renilla luciferase. NF-kB activity was determined and the results are expressed as described in Figure 3c . (c) Control (Con) and RP3-expressing MEFs were transiently transfected with the NF-kB-dependent reporter pBIIx-firefly luciferase (FFL) together with b-actin renilla luciferase (RL). Cells were also either mock transfected (À) or transiently transfected with dominant-negative (DN) NIK (NIK DN ; þ ). After 24 h, NF-kB activity was determined by dual-luciferase assay as described in Figure 3c . Lysates were immunoblotted using the antibodies specified (left). Y588F -expressing MEFs were transiently transfected with pBIIx-firefly luciferase and b-actin renilla luciferase. NF-kB activity was determined by dual-luciferase assay and the results are expressed as described in Figure 3c . (c) Expression of CCL2 in control (Con) RP3-and RP3 Y588F -expressing MEFs was measured by quantitative reverse transcriptase (qRT)-PCR and RQ levels were normalized to levels in untreated control MEFs.
NF-kB. Supershifts demonstrated that RP3 also induced the DNA-binding of p50 homodimers although the overall amount of nuclear p50 was decreased in RP3-expressing cells. Notably, the nuclear complexes induced by RP3 were very similar to those activated by TNF that only activates the classical NF-kB pathway. Previously, RET/PTCs were reported to induce a pro-inflammatory gene program hallmarked by classical NF-kB-dependent genes (Russell et al., 2003; Borrello et al., 2005) . Consistent with this, RP3-induced expression of CXCL1, CCL2, GM-CSF and TNF in MEFs. Furthermore, the amounts of IkBa and p100 that are targets of classical NF-kB (Hayden and Ghosh, 2008) were increased in RP3-expressing cells. Together, these findings support the notion that RP3 mediates proinflammatory effects through activation of the classical NF-kB pathway.
Classical NF-kB activation typically requires NEMO and IKKb but not IKKa (Hayden and Ghosh, 2008) . It is therefore notable that RP3 activates NF-kB in IKKb À/À but not IKKa À/À MEFs indicating that IKKb cannot substitute for IKKa in transducing the RP3 signal. Our study therefore identifies RP3 as a member of a subset of classical NF-kB inducers that can utilize NEMO and IKKa but do not require IKKb. This finding contradicts the data that RET-induced NF-kB activation requires IKKb (Ludwig et al., 2001) . However, RET is a transmembrane protein whereas RP3 mostly localizes to the cytoplasm (Monaco et al., 2001) . Consequently, the distinct structures, stoichiometry and localization of RP3 and RET may contribute to the separate signals activated by each protein.
Extensive efforts are focused on developing selective IKKb inhibitors to block aberrant classical NF-kB activation (Gilmore and Herscovitch, 2006) . However, because IKKa is crucial for RP3-induced NF-kB activation, we predict that targeting IKKb would not block the effects of RP3. Recent studies revealed that small molecule IKKb inhibition incompletely inhibits classical NF-kB in B-cell lymphoma cells and that concomitant ablation of IKKa is required for effective blockade (Lam et al., 2008) . Consequently, in situations such as RP3 expression in disease, NF-kB will be activated via NEMO and IKKa and thus, inhibiting NEMO function might be a more effective strategy to ablate pathological NF-kB activity. Supporting this notion, the cell-permeable NBD peptide that disrupts NEMO function inhibited RP3-induced NF-kB activation and gene expression.
Intriguingly, RP3 stabilized NIK levels in MEFs and NIK was required for RP3-induced NF-kB. Furthermore, we detected strong positive NIK expression in RET-positive PTC tissues demonstrating the potential importance of this stabilization in human disease. NIK is a key regulator of noncanonical NF-kB signaling that is minimally expressed in resting cells and accumulates only following ligation of specific receptors (Hayden and Ghosh, 2008) . Contrary to this tight physiological regulation, elevated NIK levels have been reported in multiple myeloma (Annunziata et al., 2007; Keats et al., 2007) and pancreatic cancer cells (Nishina et al., 2009; Wharry et al., 2009) . In addition, mutations in NIK or mutations in the proteins that negatively regulate NIK expression lead to the observed dysregulated NIK expression in multiple myeloma (Annunziata et al., 2007; Keats et al., 2007) . It is highly unlikely that RP3 expression itself causes mutations in NIK or in any of the genes regulating NIK expression. Hence, we conclude that RP3 aberrantly modulates the pathways that control NIK stabilization. NIK is normally maintained absent or at a low level by a TRAF2, TRAF3 and cIAP1/2 complex that ubiquitinates NIK causing its proteasomal degradation (Vallabhapurapu et al., 2008) . Ligation of specific receptors results in TRAF3 degradation and NIK accumulation (He et al., 2007; Vallabhapurapu et al., 2008; Zarnegar et al., 2008) . Surprisingly, NIK levels were stabilized by RP3 without a reduction in TRAF3 leading us to hypothesize that RP3 interferes with the normal NIK regulatory machinery. However, we did not detect any interactions between RP3 and either TRAF2 or TRAF3 and RP3 did not bind NIK, NEMO or IKKa (Supplementary Figure S4) . One possibility is that RP3 phosphorylates an unknown tyrosine residue or motif on one of the key regulatory proteins, and this ''disconnects'' NIK from the negative influence of this apparatus. Alternatively, RP3 may target an as yet unknown component of this TRAF2/3 complex or may aberrantly activate a normally unrelated protein that blocks the negative regulation of NIK expression. Recently, Razani et al. (2010) reported that IKKa has a critical role in downregulating NIK levels following noncanonical NF-kB pathway activation and these workers hypothesized that dysregulation of this mechanism may contribute to aberrant NIK expression in disease. It is therefore intriguing to consider that although RP3 activates classical NF-kB via IKKa, it may also interfere with the negative feedback from IKKa and block its ability to phosphorylate NIK. Determining which, if any, of these scenarios contribute to the ability of RP3 to bypass the normal mechanisms and relieve the negative regulation of NIK will be the subject of intense further work.
Consistent with previous studies, RP3-induced NFkB activation required the intact signaling function of RP3 as mutating a tyrosine 588 (Y588) in RP3 (Russell et al., 2003; Pufnock and Rothstein, 2009 ) abrogated NIK stabilization. Phosphorylation of the equivalent residue in RET (Y1062) generates a docking site for adaptors containing SH2 or PTB domains (Wells and Santoro, 2009 ). This tyrosine phosphorylation leads to downstream signals that activate the RAS/RAF/extracellular signal-regulated kinase/mitogen-activated protein kinase and phosphatidylinositol 3 kinase/AKT pathways (Santoro et al., 1993; Hayashi et al., 2000; Lodyga et al., 2009; Wells and Santoro, 2009 ). This same tyrosine residue, Y1062, is also required for RETinduced NF-kB activity (Hayashi et al., 2000) . We postulate that constitutive autophosphorylation of Y588 in RP3 engages similar signals that facilitate NIK stabilization by inactivating the TRAF/cIAP complex. One mechanism we explored was the phosphatidylinositol 3 kinase/AKT pathway; however, although pharmacological inhibition completely blocked RP3-induced AKT phosphorylation, NIK stabilization remained intact (Supplementary Figure S5) . Hence, we conclude that RP3-induced NIK stabilization does not involve activation of the phosphatidylinositol 3 kinase/AKT pathway. Although further work is clearly required, our findings strongly suggest that crosstalk between signals elicited at Y588 and the NIK regulatory machinery, mediates aberrant classical NF-kB activation.
In addition to their role in cancer, RET/PTCs occur in autoimmune thyroiditis with no apparent neoplasia (Muzza et al., 2009 ). Consequently, RET/PTC signaling might regulate immune cell infiltration in diseases including Hashimoto's thyroiditis, a hallmark of which is formation of lymphoid follicles in the thyroid. As noncanonical NF-kB signaling regulates lymphoid organogenesis (Hayden and Ghosh, 2008) , it is tempting to speculate that RP3-induced NIK stabilization induces this noncanonical lymphoid organogenesis gene program. However, RP3 expression did not activate noncanonical NF-kB signaling or gene expression in MEFs suggesting that the precise cellular context in which NIK is aberrantly expressed might influence noncanonical NF-kB activation. Further investigation to determine whether NIK expression correlates with thyroiditis is required; however, our data support the hypothesis that RP3-induced NIK stabilization has a role in thyroid malignancy and possibly in the development of autoimmune thyroiditis.
In conclusion, we show that the RP3 stabilizes NIK and activates classical NF-kB via NEMO and IKKa. As NF-kB activation mediates the oncogenic and proinflammatory function of RP3 (Russell et al., 2003; Pufnock and Rothstein, 2009; Pacifico and Leonardi, 2010) , our demonstration that NIK is absolutely required for RP3-induced NF-kB activation strongly suggests that NIK stabilization regulates these effects of RP3. Further intense studies will be required to address this in detail; however, our findings provide the rational basis for pursuing strategies to block aberrant NIK expression and NF-kB activation in thyroid cancer and in the highly prevalent autoimmune disease Hashimoto's thyroiditis. As the NBD peptide blocks RP3-induced NF-kB, targeting NEMO is a potentially important therapeutic approach. However, this might ablate normal classical NF-kB activity, and consequently, targeting NIK expression might be a more specific strategy. Identifying the precise mechanisms through which RP3 disconnects NIK from its regulatory complex will be crucial in this regard. Nevertheless, our findings reveal that an oncogene can bypass the negative regulatory signals controlling NIK expression resulting in stabilization of this critical signaling molecule.
Materials and methods
Antibodies
Anti-RET, IKKa, p50, NIK, TRAF3, TRAF2, RelB and NEMO were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-tubulin was from Sigma-Aldrich (St Louis, MO, USA). Anti-IKKb, phospho IKKa/b, p65, phospho-p65, IkBa, phospho-IkBa, histone H3, p100 and phospho-p100 were from Cell Signaling Technology (Beverly, MA, USA). Secondary antibodies were from Jackson ImmunoResearch Laboratories, (West Grove, PA, USA). Anti-lymphotoxin-b receptor was from BD Biosciences (San Jose, CA, USA).
Cells and tissue culture WT), IKKa
À/À and IKKb À/À MEFs were from Dr Inder Verma (The Salk Institute) and NEMO À/À cells were from Dr Michael Karin (UCSD School of Medicine). NIK À/À MEFs were a gift from Amgen Inc., (Thousand Oaks, CA, USA). All cells were maintained in Dulbecco's modified Eagle's medium
